Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$23.18 -1.2%	$24.80	$22.64 ▼ $53.96	$1.11B	0.77	494,038 shs	517,512 shs
ANW Aegean Marine Petroleum Network		$0.00	$0.60 ▼ $5.10	$26.64M	3.27	526,099 shs	N/A
CRDL Cardiol Therapeutics	$1.47 +1.4%	$1.21	$0.77 ▼ $2.63	$119.84M	1.03	310,613 shs	142,827 shs
MRK Merck & Co., Inc.	$78.94 -0.9%	$79.04	$73.31 ▼ $132.29	$200.05B	0.38	13.14 million shs	13.74 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	-4.60%	-7.46%	-4.17%	-17.72%	-42.21%
CRDL Cardiol Therapeutics	+8.21%	+9.85%	+31.82%	+46.46%	-31.60%
MRK Merck & Co., Inc.	-0.79%	+0.60%	+2.77%	-8.97%	-40.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	4.2787 of 5 stars	3.1	1.0	0.0	3.7	2.8	4.2	1.3
ANW Aegean Marine Petroleum Network	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	2.4867 of 5 stars	3.7	2.0	0.0	0.0	4.0	0.0	0.6
MRK Merck & Co., Inc.	4.9978 of 5 stars	3.2	5.0	5.0	3.9	3.0	2.5	3.8

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.25	Hold	$32.33	39.49% Upside
ANW Aegean Marine Petroleum Network	0.00	N/A	N/A	N/A
CRDL Cardiol Therapeutics	3.33	Buy	$8.00	444.22% Upside
MRK Merck & Co., Inc.	2.43	Hold	$109.19	38.32% Upside

Current Analyst Ratings Breakdown

Latest CRDL, AMPH, ANW, and MRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
5/20/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Cautious
5/14/2025	MRK Merck & Co., Inc.	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$115.00 ➝ $84.00
5/12/2025	AMPH Amphastar Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$45.00 ➝ $30.00
5/8/2025	AMPH Amphastar Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $35.00
4/22/2025	MRK Merck & Co., Inc.	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$85.00
4/17/2025	MRK Merck & Co., Inc.	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$115.00 ➝ $115.00
4/16/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/10/2025	AMPH Amphastar Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/7/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00

(Data available from 6/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$731.97M	1.49	$4.94 per share	4.69	$15.23 per share	1.52
ANW Aegean Marine Petroleum Network	$5.67B	0.00	N/A	N/A	$14.96 per share	0.00
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.22 per share	N/A
MRK Merck & Co., Inc.	$64.17B	3.09	$9.37 per share	8.42	$18.33 per share	4.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$159.52M	$2.76	8.40	7.05	6.11	19.38%	22.20%	10.40%	8/6/2025 (Estimated)
ANW Aegean Marine Petroleum Network	-$29.30M	-$0.53	N/A	0.00	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	-$26.77M	-$0.34	N/A	N/A	N/A	N/A	-209.63%	-141.09%	7/14/2025 (Estimated)
MRK Merck & Co., Inc.	$17.12B	$6.87	11.49	7.97	0.83	27.27%	43.23%	17.11%	7/29/2025 (Estimated)

Latest CRDL, AMPH, ANW, and MRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/24/2025	Q1 2025	MRK Merck & Co., Inc.	$2.16	$2.22	+$0.06	$2.01	$15.59 billion	$15.53 billion
3/31/2025	Q4 2024	CRDL Cardiol Therapeutics	-$0.08	-$0.07	+$0.01	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ANW Aegean Marine Petroleum Network	$0.03	4.58%	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
MRK Merck & Co., Inc.	$3.24	4.10%	N/A	47.16%	14 Years

Latest CRDL, AMPH, ANW, and MRK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/27/2025	MRK Merck & Co., Inc.	quarterly	$0.81	4.18%	6/16/2025	6/16/2025	7/8/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.80	2.95	2.02
ANW Aegean Marine Petroleum Network	N/A	N/A	N/A
CRDL Cardiol Therapeutics	0.01	3.26	3.26
MRK Merck & Co., Inc.	0.69	1.41	1.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
ANW Aegean Marine Petroleum Network	34.60%
CRDL Cardiol Therapeutics	12.49%
MRK Merck & Co., Inc.	76.07%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.50%
ANW Aegean Marine Petroleum Network	N/A
CRDL Cardiol Therapeutics	5.25%
MRK Merck & Co., Inc.	0.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	2,028	47.14 million	34.18 million	Optionable
ANW Aegean Marine Petroleum Network	N/A	40.64 million	N/A	Optionable
CRDL Cardiol Therapeutics	20	82.65 million	78.31 million	Not Optionable
MRK Merck & Co., Inc.	75,000	2.51 billion	2.51 billion	Optionable

CRDL, AMPH, ANW, and MRK Headlines

Recent News About These Companies

MRK - Merck & Co Inc Key Metrics - Morningstar

5 hours ago | morningstar.comM

Merck (MRK) Stock Falls Amid Market Uptick: What Investors Need to Know

June 26 at 6:51 PM | zacks.com

ACIP Recommends Use of Merck's ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season

June 26 at 1:39 PM | businesswire.com

Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?

June 26 at 10:51 AM | zacks.com

RFK Jr.’s Advisers Back Merck’s RSV Shot for Newborns

June 26 at 10:08 AM | bloomberg.com

RFK Jr.'s CDC vaccine panel backs Merck RSV shot for infants

June 26 at 10:03 AM | cnbc.com

ACIP recommends Merck's RSV shot for infants under 8 months old

June 26 at 10:01 AM | youtube.comY

US CDC panel votes in favor of Merck's RSV antibody drug

June 26 at 9:00 AM | reuters.com

Baugh & Associates LLC Acquires 10,094 Shares of Merck & Co., Inc. (NYSE:MRK)

June 26 at 7:21 AM | marketbeat.com

KPP Advisory Services LLC Increases Stake in Merck & Co., Inc. (NYSE:MRK)

June 26 at 7:20 AM | marketbeat.com

Penobscot Investment Management Company Inc. Raises Stock Position in Merck & Co., Inc. (NYSE:MRK)

June 26 at 7:02 AM | marketbeat.com

Merck & Co., Inc. (NYSE:MRK) Stake Reduced by Robeco Institutional Asset Management B.V.

June 26 at 6:42 AM | marketbeat.com

Merck & Co., Inc. (NYSE:MRK) Shares Sold by Sequoia Financial Advisors LLC

June 26 at 6:34 AM | marketbeat.com

Aspetuck Financial Management LLC Purchases Shares of 7,686 Merck & Co., Inc. (NYSE:MRK)

June 26 at 6:23 AM | marketbeat.com

Security National Bank Decreases Stake in Merck & Co., Inc. (NYSE:MRK)

June 26 at 6:14 AM | marketbeat.com

Merck & Co., Inc. (NYSE:MRK) Position Trimmed by Phillips Wealth Planners LLC

June 26 at 6:13 AM | marketbeat.com

Golden State Wealth Management LLC Boosts Stake in Merck & Co., Inc. (NYSE:MRK)

June 26 at 5:30 AM | marketbeat.com

Strategic Investment Advisors MI Decreases Stock Position in Merck & Co., Inc. (NYSE:MRK)

June 26 at 4:54 AM | marketbeat.com

Merck Moves Past 50-Day Average: How to Play MRK Stock Now

June 25 at 11:01 AM | zacks.com

Alpine Bank Wealth Management Buys New Shares in Merck & Co., Inc. (NYSE:MRK)

June 25 at 7:36 AM | marketbeat.com

Bessemer Group Inc. Cuts Stake in Merck & Co., Inc. (NYSE:MRK)

June 25 at 7:19 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL, AMPH, ANW, and MRK Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$23.18 -0.27 (-1.15%)

Closing price 04:00 PM Eastern

Extended Trading

$23.17 -0.01 (-0.04%)

As of 04:04 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Aegean Marine Petroleum Network NYSE:ANW

Aegean Marine Petroleum Network Inc., together with its subsidiaries, operates as a marine fuel logistics company that markets and supplies refined marine fuel and lubricants to vessels in port, at sea, and on rivers worldwide. The company offers fueling services to ocean-going and a range of coastal vessels, including oil tankers, container ships, drybulk carriers, cruise ships, reefers, LNG/LPG carriers, car carriers, and ferries, as well as to marine fuel traders, brokers, and other end-users of marine fuel and lubricants. It also markets and distributes marine lubricants under the Alfa Marine Lubricants brand; and provides a range of shipping services, such as technical support and maintenance, insurance arrangement and handling, financial administration, and accounting services. As of December 31, 2016, the company owned and operated a fleet of 46 bunkering vessels, including 45 double hulls and 1 single hull special purpose vehicle; 15 double hull bunkering vessels with an aggregate carrying capacity of approximately 292,400 deadweight ton (dwt); operated 10 land-based storage facilities with an aggregate storage capacity of approximately 1,075,000 cubic meters; and operated 2 vessels as floating storage facility with a cargo carrying capacity of approximately 86,800 dwt. Aegean Marine Petroleum Network Inc. was founded in 1995 and is headquartered in Athens, Greece.

Cardiol Therapeutics NASDAQ:CRDL

$1.47 +0.02 (+1.38%)

Closing price 04:00 PM Eastern

Extended Trading

$1.47 0.00 (0.00%)

As of 06:39 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Merck & Co., Inc. NYSE:MRK

$78.94 -0.73 (-0.92%)

Closing price 03:59 PM Eastern

Extended Trading

$78.99 +0.05 (+0.07%)

As of 07:59 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time